aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.002
- Book/Share 0.8259
- PB 0.8974
- Debt/Equity 0.154
- CurrentRatio 5.9328
- ROIC -0.8512
- MktCap 72617894.0
- FreeCF/Share -1.2558
- PFCF -0.5952
- PE -0.9584
- Debt/Assets 0.1159
- DivYield 0
- ROE -1.0011
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATYR | RBC Capital Mkts | Outperform | Sector Perform | -- | $1.5 | Sept. 16, 2025 |
| Downgrade | ATYR | Leerink Partners | Outperform | Market Perform | -- | $1 | Sept. 15, 2025 |
| Downgrade | ATYR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | Wells Fargo | Overweight | Equal Weight | -- | $1 | Sept. 15, 2025 |
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 01, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Dec. 1, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) have opportunity to lead the securities fraud class action lawsuit.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 27, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" …
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claims.
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Read More
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: November 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
ATYR Investors with Losses Encouraged to Contact Hagens Berman San Francisco, California--(Newsfile Corp. - November 20, 2025) - The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claims.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Nov. 18, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The new class action, King v.
Read More
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025.
Read More
Lost Money on aTyr Pharma, Inc. (ATYR)? Contact Levi & Korsinsky to Join Class Action Before December 8, 2025
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ: ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=177902&wire=5&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.
Read More
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class Action - ATYR
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" …
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) have opportunity to lead the securities fraud class action lawsuit.
Read More
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: November 13, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 13, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" …
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
Investor Alert: Deadline Approaching to Join aTyr Pharma, Inc. (ATYR) Class Action - Contact Levi & Korsinsky
Published: November 11, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 11, 2025) - If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ: ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=176751&wire=5&utm_campaign=25 or contact Joseph E. Levi, Esq.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Sanjay S. Shukla
- Employees 56